Literature DB >> 20199547

Measuring disease activity and damage in discoid lupus erythematosus.

S Wahie1, E McColl, N J Reynolds, S J Meggitt.   

Abstract

BACKGROUND: Discoid lupus erythematosus (DLE) is a disfiguring inflammatory skin disease. There is no specific tool for measuring disease severity.
OBJECTIVES: To determine the features needed in a score measuring activity and damage in DLE and to investigate the score's reliability and its correlation with the physician's global assessment of disease severity and the patient-reported Dermatology Quality of Life Index (DLQI).
METHODS: The content of the score was determined following a peer review, pilot work in patients and a preliminary inter-rater reliability study. The Score of Activity and Damage in DLE (SADDLE) measures severity of activity (erythema, scale, induration) and damage (scarring/atrophy and dyspigmentation) attributable to DLE. Summed scores range between 0 and 195. Inter- and intrarater reliability of the score was tested using six assessors and nine patients with DLE. Intraclass correlation coefficients (ICCs) > 0.7 were considered evidence of good inter- and intrarater agreement.
RESULTS: The mean +/- SD SADDLE score of nine patients in the inter-rater reliability study was 47 +/- 22 (range 14-102). There was good inter-rater agreement for the total score [ICC 0.82; 95% confidence interval (CI) 0.61-0.95] and for the activity and damage scales, the individual physical signs and the total scores at individual body sites. The total score demonstrated excellent intrarater reliability (ICC 0.98; 95% CI 0.86-1.00). Although there was poor inter-rater agreement for global assessments (ICC 0.28; 95% CI 0.06-0.66), a good correlation was demonstrated between total scores and global assessments (r = 0.7). A weaker positive correlation was observed between disease activity scores and DLQI (r = 0.4).
CONCLUSIONS: The SADDLE measures activity and damage in patients with DLE. It demonstrates good inter- and excellent intrarater agreement, over and above that for global assessment. It correlates well with global assessment scores. Further studies are required to investigate SADDLE's responsiveness to change with therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20199547     DOI: 10.1111/j.1365-2133.2010.09656.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  [Skin manifestations in lupus erythematosus: clinical aspects and therapy].

Authors:  A Kuhn; V Ruland; G Bonsmann
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

Review 2.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

3.  Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma.

Authors:  Jan Dutz; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2011-10       Impact factor: 8.551

4.  Implications of Dermoscopy and Histopathological Correlation in Discoid Lupus Erythematosus in Skin of Color.

Authors:  Balachandra S Ankad; Akash Gupta; Balkrishna P Nikam; S V Smitha; Manjula Rangappa
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

5.  Acute monolateral proptosis and orbital myositis in a patient with discoid lupus erythematosus: a case report.

Authors:  Loredana Arrico; Alessandro Abbouda; Simona Bianchi; Romualdo Malagola
Journal:  J Med Case Rep       Date:  2014-11-20

6.  Lupus Erythematosus Quality of Life Questionnaire (LEQoL): Development and Psychometric Properties.

Authors:  Elena Castellano-Rioja; María Del Carmen Giménez-Espert; Ana Soto-Rubio
Journal:  Int J Environ Res Public Health       Date:  2020-11-20       Impact factor: 3.390

Review 7.  Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need.

Authors:  Lisa N Guo; Lourdes M Perez-Chada; Robert Borucki; Vinod E Nambudiri; Victoria P Werth; Joseph F Merola
Journal:  Lupus Sci Med       Date:  2021-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.